Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
age factors (2) 2
aged (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
male (2) 2
oncology (2) 2
prognosis (2) 2
survival rate (2) 2
adult (1) 1
age (1) 1
aged, 80 and over (1) 1
analysis of variance (1) 1
anemia (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
boronic acids - therapeutic use (1) 1
bortezomib (1) 1
cancer (1) 1
chemotherapy (1) 1
clinical-trial (1) 1
dexamethasone (1) 1
disease-specific survival (1) 1
dosage and administration (1) 1
drug evaluation (1) 1
drug therapy (1) 1
drug therapy, combination (1) 1
elderly-patients (1) 1
greece (1) 1
health aspects (1) 1
hematology (1) 1
hyperviscosity (1) 1
l-lactate dehydrogenase - blood (1) 1
lenalidomide (1) 1
lymphoma (1) 1
melphalan (1) 1
middle aged (1) 1
model (1) 1
multiple myeloma (1) 1
multiple myeloma - diagnosis (1) 1
multiple myeloma - drug therapy (1) 1
multiple myeloma - mortality (1) 1
neoplasm staging - statistics & numerical data (1) 1
patient outcomes (1) 1
plus thalidomide (1) 1
prednisone (1) 1
pyrazines - therapeutic use (1) 1
randomized-trial (1) 1
renal impairment (1) 1
research (1) 1
retrospective studies (1) 1
survival (1) 1
thalidomide (1) 1
thalidomide - analogs & derivatives (1) 1
thalidomide - therapeutic use (1) 1
transplantation (1) 1
treatment outcome (1) 1
waldenstrom macroglobulinemia - diagnosis (1) 1
waldenstrom macroglobulinemia - enzymology (1) 1
waldenstrom macroglobulinemia - therapy (1) 1
waldenström (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
by Kastritis, E and Zervas, K and Symeonidis, A and Terpos, E and Delimbassi, S and Anagnostopoulos, N and Michali, E and Zomas, A and Katodritou, E and Gika, D and Pouli, A and Christoulas, D and Roussou, M and Kartasis, Z and Economopoulos, T and Dimopoulos, M.A
Leukemia, ISSN 0887-6924, 06/2009, Volume 23, Issue 6, pp. 1152 - 1157
When the novel agents thalidomide, bortezomib and lenalidomide are administered to patients with myeloma in the context of clinical trials, they are associated... 
DEXAMETHASONE | CLINICAL-TRIAL | RANDOMIZED-TRIAL | PLUS THALIDOMIDE | prognosis | CHEMOTHERAPY | TRANSPLANTATION | PREDNISONE | thalidomide | ONCOLOGY | lenalidomide | bortezomib | HEMATOLOGY | ELDERLY-PATIENTS | MELPHALAN | renal impairment | Bortezomib | Age Factors | Multiple Myeloma - diagnosis | Multiple Myeloma - mortality | Humans | Drug Evaluation | Male | Survival Rate | Treatment Outcome | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Greece | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Analysis of Variance | Female | Aged | Retrospective Studies | Thalidomide - therapeutic use | Neoplasm Staging - statistics & numerical data | Antimitotic agents | Chemotherapy | Patient outcomes | Multiple myeloma | Dosage and administration | Research | Drug therapy, Combination | Antineoplastic agents | Drug therapy | Health aspects | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase
by Kastritis, Efstathios and Zervas, Konstantinos and Repoussis, Panagiotis and Michali, Evridiki and Katodrytou, Eirini and Zomas, Athanasios and Simeonidis, Argiris and Terpos, Evangelos and Delimbassi, Sossana and Vassou, Amalia and Gika, Dimitra and Dimopoulos, Meletios A and Greek Myeloma Study Grp and Greek Myeloma Study Group
Clinical Lymphoma & Myeloma, ISSN 1557-9190, 03/2009, Volume 9, Issue 1, pp. 50 - 52
We analyzed 232 patients with previously untreated, symptomatic WM, of whom 10% were <= 50 years of age and 21% were > 75 years of age. Disease features and... 
Hyperviscosity | Waldenström | Anemia | Disease-specific survival | Age | SURVIVAL | ONCOLOGY | LYMPHOMA | MODEL | Prognosis | Age Factors | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Male | Survival Rate | L-Lactate Dehydrogenase - blood | Aged, 80 and over | Adult | Female | Aged | Waldenstrom Macroglobulinemia - enzymology | Waldenstrom Macroglobulinemia - diagnosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.